Arrowhead Reports 20.84% ROIC vs 9.86% WACC, Outpacing Most Peers
Arrowhead Pharmaceuticals achieved a ROIC of 20.84% against a WACC of 9.86%, yielding a ROIC/WACC ratio of 2.11 and signaling efficient capital deployment. This performance outpaces peers like Alnylam (-10.44% ROIC) and Amicus (-13.65% ROIC) but trails ACADIA’s 23.32% ROIC leadership.
1. Strong Capital Efficiency Metrics
Arrowhead Pharmaceuticals posted a 20.84% return on invested capital compared with a 9.86% weighted average cost of capital, resulting in a ROIC/WACC ratio of 2.11. This indicates the company generates more than double its capital cost in returns, underscoring efficient deployment of resources.
2. Comparison with Peers
Among major biopharma peers, Arrowhead’s 20.84% ROIC stands in contrast to Alnylam’s -10.44% and Amicus’s -13.65%, both of which fall below their respective WACCs. This comparative strength suggests Arrowhead holds a competitive advantage in converting R&D and operational investments into returns.
3. ACADIA’s Leading Performance
ACADIA Pharmaceuticals leads the group with a 23.32% ROIC against a 6.74% WACC, yielding a ratio of 3.46. While Arrowhead demonstrates strong capital efficiency, ACADIA’s superior spread highlights its exceptional growth potential and positions it as the top peer for investors seeking high ROIC.